Browsing by Subject "A61P 35/00"
Now showing items 1-20 of 22
-
(United States. Patent and Trademark Office; Texas A&M University. Libraries, 2010-06-15)Provided herein are compositions, all related stereoisomers as well as pharmaceutically acceptable salts provided as simplified analogs of pateamine A, in which the analogs generally are devoid of the C3-amino and C5-methyl ...
-
(United States. Patent and Trademark Office; Texas A&M University. Libraries, 2012-02-21)Derivatives of belactosin and their synthesis are disclosed. In certain embodiments, compounds of the present invention exhibit anti-cancer, antiviral, antibiotic, and/or auto-immune therapeutic abilities. In general, ...
-
(United States. Patent and Trademark Office; Texas A&M University. Libraries, 2012-09-04)The present invention provides compounds having the general structure A, or a pharmaceutically acceptable derivatives thereof: wherein R is an alkyl group, and R1 comprises at least one moiety selected from a group ...
-
(United States. Patent and Trademark Office; Texas A&M University. Libraries, 2012-04-03)The present embodiment of the invention is generally directed to compositions comprising suspensions of poorly water soluble compounds recrystallized in nanoparticulate sizes ranging from 0.1 to 5 ?m. In addition, the ...
-
(United States. Patent and Trademark Office; Texas A&M University. Libraries, 2013-03-05)The present embodiment of the invention is generally directed to compositions comprising suspensions of poorly water soluble compounds recrystallized in nanoparticulate sizes ranging from 0.1 to 5 ?m. In addition, the ...
-
(United States. Patent and Trademark Office; Texas A&M University. Libraries, 2015-02-17)Provided herein are methods directed to modulating the pro-oncogenic effects of noncoding RNAs (ncRNAs) through their interactions with specificity protein transcription factors (SpTFs). In one aspect, the disclosure ...
-
(United States. Patent and Trademark Office; Texas A&M University. Libraries, 2018-01-16)The disclosure provides rifamycin and rifamycin derivative compositions, including rifabutin and rifabutin derivative compositions able to cause drug-sensitization in a cancer cell or inhibition of a cancer cell. The ...
-
(United States. Patent and Trademark Office; Texas A&M University. Libraries, 2007-06-19)Disclosed are methods and compositions for the treatment of a wide array of cancers and tumors. In illustrative embodiments, diindolylmethanes, C-substituted diindolylmethanes, and analogs thereof have been described, which ...
-
(United States. Patent and Trademark Office; Texas A&M University. Libraries, 2008-07-29)The present invention provides organic arsenicals. Many of these compounds have potent in vitro cytotoxic activity against numerous human tumor cell lines, both of solid and hematological origin, as well as against malignant ...
-
(United States. Patent and Trademark Office; Texas A&M University. Libraries, 2012-07-17)The present invention provides organic arsenicals which may be used to treat numerous human tumor cell lines, both of solid and hematological origin, as well as against malignant blood cells from patients with leukemia.
-
(United States. Patent and Trademark Office; Texas A&M University. Libraries, 2010-05-04)Disclosed are methods and compositions for the treatment of a wide array of cancers and tumors. In illustrative embodiments, diindolylmethanes, C-substituted diindolylmethanes, and analogs thereof have been described, which ...
-
(United States. Patent and Trademark Office; Texas A&M University. Libraries, 2000-10-24)Methods and pharmaceutical combinations for inhibiting estrogen-dependent tumors via the co-administration of antiestrogen triphenylethylenes, including tamoxifen, and alkyl PCDFs.
-
(United States. Patent and Trademark Office; Texas A&M University. Libraries, 2013-03-05)The present invention relates to novel derivatives of glycyrrhetinic acid, compositions comprising said derivatives and their use in the treatment of conditions or diseases that benefit from an upregulation of PPAR&ggr ...
-
(United States. Patent and Trademark Office; Texas A&M University. Libraries, 2014-09-23)Provided herein include compositions, all related stereoisomers as well as pharmaceutically acceptable salts provided as simplified analogs of pateamine A, in which the analogs generally are devoid of the C3-amino and ...
-
(United States. Patent and Trademark Office; Texas A&M University. Libraries, 2007-06-12)The present invention provides a compound of Formula I, all of its related stereoisomers, and their pharmaceutically acceptable salts, wherein A—B, K, Q, X, Y, Z, R and R1 are as defined in Claim 1. The present invention ...
-
(United States. Patent and Trademark Office; Texas A&M University. Libraries, 2007-10-09)The present invention involves a recombinant virus which comprises at least one foreign nucleic acid inserted within a non-essential region of the viral genome of a virus, wherein each such foreign nucleic acid encodes a ...
-
(United States. Patent and Trademark Office; Texas A&M University. Libraries, 2005-06-28)Arsenic trioxide, an inorganic compound, is commercially available anti-cancer agent but it carries significant toxicity. Organic arsenicals, on the other hand, are much less toxic, to the extent that the methylation of ...
-
(United States. Patent and Trademark Office; Texas A&M University. Libraries, 2009-11-17)Arsenic trioxide, an inorganic compound, is commercially available anti-cancer agent but it carries significant toxicity. Organic arsenicals, on the other hand, are much less toxic, to the extent that the methylation of ...
-
(United States. Patent and Trademark Office; Texas A&M University. Libraries, 2006-02-07)Arsenic trioxide, an inorganic compound, is commercially available anti-cancer agent but it carries significant toxicity. Organic arsenicals, on the other hand, are much less toxic, to the extent that the methylation of ...
-
(United States. Patent and Trademark Office; Texas A&M University. Libraries, 2009-04-07)The present invention identified a high affinity binding sequence in collagen type III for the collagen-binding integrin I domains. Provided herein are the methods used to characterize the sequence, the peptides comprising ...